Lilly’s revenue soars 48%, driven by demand for its GLP-1s
Lilly’s sales were driven by higher-than-expected demand for Mounjaro and Zepbound, its GLP-1 drugs for Type 2 diabetes and weight loss.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
- Who's exposed
- LLYEli Lilly and Up
Companies named in the story.
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief


